Episode notes
When Akero’s stock dropped after a trial setback, why did RTW double down that same day? CEO Andrew Cheng joins RTW’s Rod Wong to share how he navigated the biotech storm, why he believed in efruxifermin (EFX,) and what’s next for liver disease treatment.
PODCAST TEAM
Producer: Devon Leaver
Editor: Dominique Guerra
Production Coordinator: YingYu Lin
Featuring: Andrew Cheng, CEO of Akero Therapeutics, moderated by Roderick Wong, MD, Managing Partner and Chief Investment Officer RTW Investments.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out
Keywords
life scienceshealthcare investingbiotechscienceMASHcirrhosis